Galectin Therapeutics Inc. (GALT)
GALT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GALT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001133416 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements." | 10-Q 2026-08-14 |
| Cash and burn | $13.3M cash; operating cash flow -$4.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 100,849,644 (2026-08-06); 64,060,262 a year earlier; 59,582,253 three years earlier. | Cover page 2026-08-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Atlanta, Georgia, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $23K, sold $6.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$9.1M | -$2.4M | $13.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$5.0M | -$3.9M | $14.1M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$5.5M | -$6.0M | $17.7M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$8.2M | -$3.5M | $11.5M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$7.5M | -$6.6M | $13.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$9.6M | -$7.7M | $7.4M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$12.0M | -$12.8M | $15.1M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$11.2M | -$8.5M | $27.1M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-31 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-10-13 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.9% |
| 1 month | -17.3% |
| 3 months | -13.6% |
| Year to date | -26.7% |
| 1 year | -44.8% |
| From 52-week high | -53.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| EBS | Emergent BioSolutions Inc. | $5.81 | +0.35% | $298.7M |
| EVMN | Evommune Inc. | $7.10 | -6.95% | $293.6M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| AVIR | Atea Pharmaceuticals Inc. | $4.12 | -4.19% | $330.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier